- Home
- RAND vs NRSN Comparison
RAND vs NRSN Comparison
Compare RAND & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- NRSN
- Stock Information
- Founded
- RAND 1969
- NRSN 2017
- Country
- RAND United States
- NRSN Israel
- Employees
- RAND N/A
- NRSN N/A
- Industry
- RAND Finance: Consumer Services
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- NRSN Health Care
- Exchange
- RAND Nasdaq
- NRSN Nasdaq
- Market Cap
- RAND 57.6M
- NRSN 58.8M
- IPO Year
- RAND N/A
- NRSN 2021
- Fundamental
- Price
- RAND $15.48
- NRSN $2.35
- Analyst Decision
- RAND
- NRSN Buy
- Analyst Count
- RAND 0
- NRSN 2
- Target Price
- RAND N/A
- NRSN $14.00
- AVG Volume (30 Days)
- RAND 6.1K
- NRSN 408.0K
- Earning Date
- RAND 08-05-2025
- NRSN 07-01-2025
- Dividend Yield
- RAND 7.47%
- NRSN N/A
- EPS Growth
- RAND 39.77
- NRSN N/A
- EPS
- RAND 3.12
- NRSN N/A
- Revenue
- RAND $8,499,970.00
- NRSN N/A
- Revenue This Year
- RAND N/A
- NRSN N/A
- Revenue Next Year
- RAND N/A
- NRSN N/A
- P/E Ratio
- RAND $4.98
- NRSN N/A
- Revenue Growth
- RAND 12.52
- NRSN N/A
- 52 Week Low
- RAND $14.01
- NRSN $0.51
- 52 Week High
- RAND $31.89
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- RAND 42.20
- NRSN 71.85
- Support Level
- RAND $15.15
- NRSN $1.90
- Resistance Level
- RAND $15.75
- NRSN $2.60
- Average True Range (ATR)
- RAND 0.52
- NRSN 0.21
- MACD
- RAND 0.14
- NRSN 0.03
- Stochastic Oscillator
- RAND 36.67
- NRSN 75.49
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.